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Yersinia pestis, the causative agent of plague, utilizes a plasmid-encoded type III secretion system (T3SS) to
aid it with its resistance to host defenses. This system injects a set of effector proteins known as Yops (Yersinia
outer proteins) into the cytosol of host cells that come into contact with the bacteria. T3SS is absolutely
required for the virulence of Y. pestis, making it a potential target for new therapeutics. Using a novel and
simple high-throughput screening method, we examined a diverse collection of chemical libraries for small
molecules that inhibit type III secretion in Y. pestis. The primary screening of 70,966 compounds and mixtures
yielded 421 presumptive inhibitors. We selected eight of these for further analysis in secondary assays. Four
of the eight compounds effectively inhibited Yop secretion at micromolar concentrations. Interestingly, we
observed differential inhibition among Yop species with some compounds. The compounds did not inhibit
bacterial growth at the concentrations used in the inhibition assays. Three compounds protected HeLa cells
from type III secretion-dependent cytotoxicity. Of the eight compounds examined in secondary assays, four
show good promise as leads for structure-activity relationship studies. They are a diverse group, with each
having a chemical scaffold not only distinct from each other but also distinct from previously described
candidate type III secretion inhibitors.
Yersinia pestis, a gram-negative bacterium in the family En-
terobacteriaceae, is the causative agent of plague (10). A hall-
mark of this devastating disease is the rapid development of
systemic infection following the deposition of a small inoculum
into the skin via the bite of an infected flea (9). This fulminant
course is dependent on the ability of the bacteria to overwhelm
host defenses, a feat which they accomplish by a combination
of stealth and active suppression targeting innate immune
mechanisms. The type III secretion (T3S) system (T3SS) of Y.
pestis is crucial to the suppression arm of this strategy. This
system injects a set of effector proteins directly into the cyto-
plasm host cells in contact with the bacteria. These act to
derange key defensive functions, including phagocytosis and
cytokine production (11, 12).
Although several other adaptations also play key roles in
virulence, the loss of T3S is sufficient to render Y. pestis com-
pletely avirulent, even when the bacteria are introduced di-
rectly into the bloodstream (39). T3SS is shared by Y. pseudo-
tuberculosis and Y. enterocolitica, which are also pathogenic for
humans, and is encoded by a 70-kb plasmid, termed pCD1 in
most Y. pestis strains (3, 11, 17). The major injected Yersinia
outer proteins (Yops), usually designated YopH, YopE,
YopM, YopJ, YopO, and YopT, target the cytoskeleton,
proinflammatory signaling pathways, and probably other cell
functions as well. T3SS involves at least 39 other proteins that
play supporting roles in regulation, secretion, and transloca-
tion. Some notable members of this cast include the secreted
translocon proteins YopB and YopD, which collaborate to
form a pore in the host cell membrane; YscF, which forms the
shaft of a needle-like channel through which the secreted pro-
teins are thought to travel (16, 34); LcrV, which sits at the tip
of this needle and which may serve as the interface with the
YopB-YopD pore (26); and a set of chaperones (SycD, SycE,
SycH, SycT, and SycN) that assist with the translocation of
specific Yops (11, 36, 38, 40). The energy driving the secretion
process is provided by the ATPase YscN (4).
T3SSs are also present in many other gram-negative patho-
gens. Examples include Salmonella spp., Shigella spp., Pseudo-
monas aeruginosa, enteropathogenic Escherichia coli (EPEC),
enterohemorrhagic E. coli, and Chlamydia spp. Many details
regarding their workings remain to be determined, but there is
no doubt that they are both common and play important roles
in bacterial virulence (11, 18). For these reasons, they consti-
tute a potential target for novel therapeutics. Several attempts
have been to identify small-molecule T3SS inhibitors, with
some success (1, 19, 22, 23).
The regulation of the T3SS function in the yersinae is inter-
esting and unusual, offering distinct advantages for in vitro
manipulation and the development of screening techniques. At
temperatures below about 34°C, the expression of many of the
proteins required for assembly of the functional T3SS appara-
tus, known as the injectisome, is repressed. Above this tem-
perature the apparatus is formed, but under physiological con-
ditions it secretes little or no protein unless contact is made
with cell membranes. Such contact both triggers secretion by
an as yet undetermined mechanism and results in the increased
expression of many Yop genes (5, 32, 33, 37).
In vitro, high levels of secretion and Yop gene expression
can be induced by a lack of Ca2 ions in the medium during
incubation at 37°C. However, when secretion is induced in this
way, the bacteria are unable to grow (25). The increased tran-
scription of yopE under these conditions was the basis of the
technique used by Kauppi et al. to screen a library of 9,400
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compounds for their ability to inhibit T3SS in Y. pseudotuber-
culosis (22). We took advantage of the inhibition of growth that
accompanies the secretion induced by low levels of calcium to
devise an alternative screening technique. Here, we describe
this method and report on the initial characterization of a
novel set of inhibitors of Yersinia T3S, identified through the
screening of 70,966 compounds and mixtures from 13 small-
molecule and extract libraries.
MATERIALS AND METHODS
Bacterial strains, plasmids, and growth conditions. The Y. pestis strains used
in this study were derivatives of Y. pestis strain KIM. The strains and the plasmids
used are listed in Table 1. Plasmid pMM85 (YopE-Bla) (24) was the gift of Olaf
Schneewind (University of Chicago).
Y. pestis and Y. pseudotuberculosis were cultured in TB broth (1% [wt/vol]
Bacto tryptose [BD Bioscience], 0.5% [wt/vol] NaCl, 0.3% [wt/vol] beef extract
paste [BD Bioscience]) and brain heart infusion (BHI; BD Bioscience) broth, as
indicated. For high-throughput screening, Y. pestis was grown in TB broth for
20 h at 26°C and diluted to 1  104 bacteria/ml, the compounds to be screened
were added, and the bacterial cultures were then shifted to 37°C and incubated
for 18 h. To monitor the cultures for the secretion of Yops, Yersinia strains were
grown in BHI broth at 30°C overnight, diluted to an optical density at 600 nm
(OD600) of 0.04 in fresh BHI broth, and incubated at 30°C to an OD600 of 0.2.
The culture was then shifted to 37°C, and incubation was continued for an
additional 2 h. EPEC strains were cultured in LB medium at 37°C, unless
indicated otherwise.
Compounds and antibodies. The compounds and extract libraries used in the
screening were provided by the NIH-supported National Screening Laboratory
at Harvard Medical School. Larger quantities of the test compounds were ob-
tained from commercial venders. Compounds 1, 2, and 3 were purchased from
TimTec Inc.; compound 3 diproprionate was purchased from Sigma-Aldrich; and
compound 4 and INP0007 were purchased from ChemBridge Corporation.
Mouse monoclonal anti-YopM antibody (1A1), rabbit polyclonal anti-YopD
antibody (5331), and rabbit polyclonal anti-YopH antibody (G5788) were gifts
from Susan Straley (University of Kentucky). A rabbit polyclonal anti-YopE
antibody was the gift of Olaf Schneewind (University of Chicago). Mouse anti-
hemagglutinin (anti-HA) monoclonal antibody HA.11 was purchased from Co-
vance, and rabbit anti-OmpA antibody was kindly provided by Carol Kumamoto
(University of Massachusetts Medical School).
Construction of Y. pestis strain JG401. Random mutagenesis of pCD1 with the
transposon magellen3 (35), which confers kanamycin resistance, was used to
create pCD1 (Y0093::magellen3). Mutagenesis was performed with Y. pestis by
using the suicide delivery plasmid pFD1 (35) in donor strain 2155 (14). For
brevity, plasmid pCD1 (Y0093::magellen3) is hereafter referred to as pCD1K.
Plasmid pML001 carries the lux operon from Photorhabdus luminescens. Both
pCD1K and pML001 were introduced into Y. pestis JG154 by electroporation to
generate JG401. JG406 is a spontaneous segregant of JG401 lacking pCD1K and
was isolated by selection for growth at 37°C (31). The luminescence of the
bacterial cultures was measured with a Packard Picolite luminometer (United
Technologies) and an EnVision plate reader (Perkin-Elmer).
HTS. High-throughput screening (HTS) was conducted with luminescent Y.
pestis strain JG401. Thirty microliters of JG401 culture (1  104 bacteria/ml) was
added into each well of 384-well cell culture plates by a liquid-handling robot (a
Fill plate dispenser with a Bio-Stack apparatus, both of which were from
Bio-Tek Instruments). One hundred nanoliters of screening compound (5 mg/ml
in dimethyl sulfoxide [DMSO]) was applied to each well of the assay plates by an
Epson compound transfer robot with Epson standard-volume pin arrays. The
plates were incubated overnight at 37°C, and the relative luminescence was
measured by a plate-reading luminometer equipped with a 40-plate automatic
loader (EnVision plate reader; Perkin-Elmer). The dwell time per well was set at
0.1 s. Statistical analysis of the primary screening results was carried out as
described previously (31).
Assay of effector protein secretion. Overnight cultures of strains JG153 and
JG154 were grown as indicated above in TB broth at 30°C and were used to
inoculate BHI broth to an OD600 of 0.04. The cultures were then grown at 30°C
in glass tubes (18 by 150 mm) and aerated by rotation on a Rollordrum apparatus
(New Brunswick). When the OD600 reached 0.2, the compounds under test were
dissolved in DMSO and were then added at the indicated concentrations. The
final concentration of DMSO in all cultures except those with compound 3
diproprionate, including the controls, was 0.3%; in experiments with compound
3 diproprionate, no DMSO was used. The cultures were then shifted to 37°C to
induce T3S and were incubated for an additional 2 to 3 h. The culture superna-
tants were collected following centrifugation (3,200  g, 10 min). Proteins were
precipitated from 2 ml of supernatant with 10% (final concentration) trichloro-
acetic acid (TCA), washed twice with 1 ml of 1:1 (vol/vol) ethanol-ether, and
dissolved in 30 l water. Ten microliters of this solution, which was mixed with
sample buffer, was used to load a single lane for sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis (SDS-PAGE) and subsequent preparation of
Western blots for YopM, YopH, and YopD. Development of the Western blots
was stopped before the positive Yop controls reached saturation, and the inten-
sity and area of each band were quantified by video densitometry.
Effects of compounds on bacterial growth. Mid-log-phase cultures were di-
luted to an OD600 of 0.05 in TB broth containing 2.5 mM CaCl2. Two hundred
microliters of the culture was added to each well of 96-well tissue culture plates
(Falcon Microtest, catalog number 353072; Becton Dickinson). A total of 0.6 l
of 20 mM test compounds was added to the wells (final concentration, 60 M).
The 20 mM stocks of compounds 1 to 4 were prepared in DMSO, and the
compound 3 diproprionate stocks were prepared in water. The cultures were
TABLE 1. Bacterial strains and plasmid useda
Strain or plasmid Genotype Key properties Reference
Y. pestis strainsb
JG401 KIM pgm/pMT1, pCD1, pCD1K, pPCP1/pML001 Luminant, T3S 31
JG406 KIM pgm/pMT1, pCD1, pPCP1/pML001 Luminant, T3S 31
JG153 KIM pgm/pMT1, pCD1, pPCP1 T3S 31
JG154 KIM pgm/pMT1, pCD1, pPCP1 T3S 31
E. coli strains
2155 thrB1004 pro thi strA hsdS lacZM15 (F lacZM15 laclq
traD36 proA proB) dapA::erm pir::RP4
Supports replication and
mobilization of pFD1
14
KC14 JPN15/pMAR7 tir::cat Tir 8
KC21 JPN15/pMAR7 LEE::cat T3S 27
Plasmids
pML001 pBR322 derivative containing luxABCD Confers luminescence 31
pCD1K pCD1 Y0093::magellan3 T3S 31
pMM85 pHSG576 yopE::bla YopE -lactamase 24
pKC17 pK184 HA-tirEPEC cesT Expresses HA-Tir 8
pFD1 pGP704 magellan3, Himar1 transposase Suicide vector for delivery
of magellan3
14
a Superscript minus signs indicate negativity for the plasmid, protein, or secretion; and superscript plus signs indicate positivity.
b All Y. pestis strains were avirulent.
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incubated in a Spectra Max 250 plate reader (Molecular Devices) at 37°C with
continuous agitation (the automix function was activated). The OD600 of the
200-l culture volume was measured at 6-min intervals for 24 h, and the values
were corrected to the standard OD600 (with a cuvette with a 1-cm path length)
by using equation 1. This equation was derived by measuring the OD600 values
of 10 samples of various densities in both a standard cuvette with a 1-cm path
length and the 96-well plate. The growth rates were calculated from the expo-
nential portion of the resulting growth curves.
OD600 200 l	 0.201OD600 0.003 (1)
where R2 is equal to 0.999 for 1.6  OD600  0.06.
Cytotoxicities of test compounds. HeLa cells were maintained at 37°C with 5%
CO2 in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen) supple-
mented with 10% heat-inactivated fetal bovine serum (FBS), 100 U ml1 pen-
icillin, and 100 g ml1 streptomycin. A total of 1  105 HeLa cells/well were
seeded in a 24-well tissue culture plate in DMEM with 3% heat-inactivated FBS
1 day prior to the assay. The test compounds were applied, and the cells were
incubated at 37°C for 3 h. The level of disruption of the cell monolayer was
recorded as the percentage of cell detachment from the culture plate. The
amount of lactate dehydrogenase (LDH) released from the HeLa cell cultures
was measured with a cytotoxicity detection kit (Roche), according to the man-
ufacturer’s protocol.
T3S-mediated cytotoxic response. HeLa cell monolayers grown in DMEM
supplemented with 3% heat-inactivated FBS and 24 M HEPES (pH 7.4) were
infected with Y. pestis, and the test compounds were immediately added. The in-
fected cultures were then incubated at 37°C with 5% CO2. HeLa cells were
infected with pCD1-positive Y. pestis strains, as indicated above. The cytotoxic
response was initially observed as the rounding up of the cells. The level of
inhibition of this response was obtained by determining the percentage of the
HeLa cells that showed morphological changes among all treated cells. Strain
JG154 was used as a T3S-negative control.
Translocation of a YopE-Bla fusion protein into HeLa cells. HeLa cells were
maintained as described above. One day prior to infection, 3.5  104 cells
were seeded in each well of 24-well plates. Two hours before infection, the
cells were washed with phosphate-buffered saline and 350 l of DMEM with
24 M HEPES was added to each well. HeLa cells were infected with
mid-log-phase YopE::Bla-expressing Y. pestis strains [either JG153(pMM85)
or JG154(pMM85), as indicated] at a multiplicity of infection of 10 for 3 h.
The -lactamase substrate CCF2-AM (Invitrogen) was added to live cells at
the concentration indicated by the manufacturer. The cells were incubated at
room temperature for 1 to 2 h and were then analyzed by fluorescence
microscopy with a Nikon Eclipse E800 microscope with a -lactamase filter
set (Chroma).
Tir secretion in EPEC culture. Assays for determination of EPEC T3S were
performed as described previously (15). Briefly, KC14(pKC17) (8) or
KC21(pKC17) (8, 27) cultures were grown in LB medium at 37°C for approxi-
mately 8 h, diluted 1:500 into prewarmed DMEM-HEPES, and grown in a 5%
CO2 atmosphere overnight. Overnight cultures were further diluted 1:50 into 5
ml of prewarmed DMEM-HEPES and grown in a 5% CO2 atmosphere at 37°C
for 2 h. Test compound dissolved in DMSO or DMSO alone was added to the
cultures, and incubation was continued for an additional 8 h. To separate the
bacteria from the secreted proteins, the cultures were centrifuged at 3,300 g for
10 min and the supernatant was passed through a 0.45-m-pore size low-protein-
binding filter. The bacterial pellet was resuspended in 50 l of loading buffer,
boiled for 10 min, and subjected to SDS-PAGE; and immunoblots were pre-
pared. The secreted proteins were precipitated with 10% cold TCA overnight at
4°C, and immunoblots were prepared as described above.
RESULTS
Basis of the screening method. As noted above, our screen-
ing technique is based on peculiarities of the physiology of Y.
pestis that are not well understood. The combination of low
concentrations of calcium ions (
1 mM) and incubation at
temperatures above 34°C strongly induces the expression of
T3SS and results in the secretion of the Yop effector proteins
directly into the surrounding medium (12, 25, 42). Note that
this is distinct from the targeted secretion accomplished by this
system during cell contact, in which effector proteins are di-
rected into the cells at physiological Ca2 concentrations
(2.5 mM). The low-calcium-concentration-dependent induc-
tion of T3S is also accompanied by the inhibition of bacterial
growth. In certain media with very low sodium ion concentra-
tions, this growth inhibition is weak or absent (6, 7), suggesting
that the leakage of Na into the cells through the active section
apparatus may be the key factor in growth inhibition. Whatever
its true cause, we reasoned that at least some inhibitors of T3S
would prevent this growth inhibition and could be detected on
this basis.
To implement the screening, we constructed a specialized Y.
pestis strain. This strain was rendered avirulent both by a large
spontaneous chromosomal deletion that removed the genes
needed for iron acquisition during infection and by the elimi-
nation of native plasmid pPCP1, which encodes an outer mem-
brane protease (Pla) also required for full virulence. This com-
bination of lesions has been shown to result in avirulence in a
primate model of pneumonic plague (41). This strain was also
made luminescent through addition of the lux operon from
Photobacterium luminescens, carried by plasmid pML001. T3SS
in Y. pestis is encoded by a 70-kb plasmid designated pCD1.
Either segregation of this plasmid or internal deletions which
compromise the T3SS function, both of which occur at appre-
ciable frequencies, would give rise to false-positive results in a
T3S inhibition assay. To circumvent this problem, we modified
pCD1 by insertion of a version of a transposon mariner carry-
ing a kanamycin resistance determinant, magellen3 (35). In
addition to providing a means for imposing selection against
segregation, we reasoned that the insertion of magellen3 at
some locations within pCD1 might reduce the rate of sponta-
neous deletions affecting T3SS expression, either through tight
linkage with the sequences most subject to spontaneous dele-
tion or by some other means. Accordingly, we screened ran-
dom magellen3 insertion mutants of pCD1 for their frequency
of colony formation on medium with a low calcium concentra-
tion supplemented with kanamycin at 37°C: only bacteria with
defects in T3S can form colonies on this medium. One mutant
that showed markedly reduced plating efficiencies (
108) had
an insertion in the putative helicase gene, Y0093. Due to its high
degree of stability, pCD1(Y0093::magellen3) (i.e., pCD1K) was
used in the screening strain, and that strain was designated JG401.
Screening. The HTS assay, illustrated in Fig. 1A, is extremely
simple to perform. Y. pestis strain JG401 suspended in TB
broth containing 1 mM ethylene glycol-bis(-aminoethyl
ether)-N,N,N,N-tetraacetic acid to sequester low levels of
intrinsic Ca2 was distributed into 384-well plates, followed by
pin transfer of the compounds to be screened. After overnight
incubation at 37°C, the luminescence of each well was mea-
sured. Elevated luminescence implies growth and, hence, the
presumptive inhibition of T3S.
We screened 10 commercially available small-molecule li-
braries and three plant extract libraries, listed in Table S1 in
the supplemental material. They contained 69,093 individual
compounds and 1,873 plant extracts. Measurements of lumi-
nescence were interpreted relative to the luminescence of neg-
ative controls, to which no compound was added, and positive
controls supplemented with CaCl2 (final concentration, 2.5
mM) rather than a test compound.
HTS data analysis. We performed statistical analysis as de-
scribed previously (31). We chose a twofold elevation of lumi-
nescence relative to that for the controls receiving no test
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compound as the threshold for the indication of presumptive
inhibition. The effects of the compounds on luminescence are
summarized as a distribution in Fig. 1B. A total of 421 com-
pounds and extracts were identified as primary HTS hits. On
the basis of the intensity of the inhibition, the novelty of the
chemical structures, commercial availability, and the correla-
tion of our results with the results of other screens for unre-
lated activities performed at the National Screening Labora-
tory, we selected eight strong and moderate hits from the
primary hits for further detailed study. Below, we report on the
results of follow-up studies with these eight compounds which
gave moderate or strong signals in the preliminary assay.
Four of the eight compounds are T3S inhibitors. In the
primary screening, we observed that the selected compounds
were able to promote Y. pestis growth and/or luminescence at
37°C in the absence of Ca2. To determine the validity of our
assumption that some compounds with this effect would be
bona fide T3S inhibitors, direct assays of T3S were performed.
Three T3S substrates, YopH, YopM, and YopD, were chosen
as secretion indicators to evaluate the compounds. Both YopH
and YopM are delivered to the cytoplasm of target cells and
play important roles in virulence. YopD is delivered to the
cytoplasmic membrane of host cells, where, in combination
with YopB, it forms pore-like structures that are required for
the translocation of other proteins across the membrane (11,
12). The effects of the eight selected compounds on YopM,
YopH, and YopD secretion were determined in assays without
target cells, in which secretion was induced by shifting bacterial
cultures in medium with a low concentration of Ca2 from
26°C to 37°C (for details, see Materials and Methods). To
detect the secreted proteins, culture supernatants were sub-
jected to SDS-PAGE, followed by Western blotting with anti-
bodies specific for each of the Yops. Four of the compounds,
designated compounds 1 to 4, showed a concentration-depen-
dent inhibition of secretion. The other four compounds did not
inhibit secretion (data not shown). The structures of com-
pounds 1 to 4 are shown in Fig. 2, and their effects in secretion
assays are shown in Fig. 3. Interestingly, differential inhibition
of secretion among the Yop species was observed with
compounds 1 and 3. Compound 1 inhibited YopH and YopM
secretion with a 50% inhibitory concentration (IC50) of ap-
proximately 10 M, but for YopD secretion, it was clear that
inhibition was very weak (Fig. 3A). Compound 3 inhibited
YopH secretion with an IC50 of 15 M; at about 15 M, its
level of inhibition of YopD approached 50%, but the level of
inhibition decreased at higher concentrations. Its inhibition
of YopM secretion was barely observable (Fig. 3C). The
IC50 of compound 2 was about 10 M for all three Yops.
Compounds 1 to 4 do not inhibit Y. pestis growth. The pri-
mary screening assay is dependent on increased luminescence,
which is used as a surrogate for increased growth. One advan-
tage of this approach is the ability to reject compounds that act
indirectly on the inhibition of secretion via their toxic effects
that result in growth inhibition. In order to confirm that the
selected compounds do not negatively affect the growth of Y.
pestis, we monitored the OD600s of the bacterial cultures in the
presence of the compounds (60 M) under conditions in which
T3S is not induced. None of the four compounds showed an
FIG. 1. HTS. (A) The HTS strategy. In Y. pestis, T3S is induced and
growth is concomitantly inhibited during incubation at 37°C in medium
lacking Ca2. Some classes of small molecules that block T3S are
expected to relieve this T3S-mediated growth inhibition. Measurement
of the luminescence of the bacteria provides a sensitive method of
measuring bacterial growth and, hence, of identifying presumptive T3S
inhibitors. (B) Distribution of photon flux among primary hits from the
HTS. Data from the screening of 70,966 compounds in duplicate were
collected and analyzed. The active compounds (see Materials and
Methods for details) were categorized into strong (100%  photon
flux  50%), medium (50%  photon flux  25%), and weak (25% 
photon flux 10%) hits and numbered 6 (0.01%), 40 (0.06%), and 375
(0.54%) compounds, respectively.
FIG. 2. Lead compounds and Y. pestis growth. Chemical structures
of compounds 1 to 4: compound 1, 5-cyano-6-(4-methylbenzylthio)pic-
olinic acid (CAS number 329057-04-7); compound 2, 4,4-thiobis(3-
methylphenol) (CAS number 3530-35-6); compound 3, 1,3-bis[3-(4,5-
dihydro-1H-imidazol-2-yl)phenyl]urea (CAS number 27885-92-3);
compound 4, 5-oxo-5-[5-(1-phenyl-3-p-tolyl-1H-pyrazol-4-yl)-3-(thio-
phen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl]pentanoic acid (CAS number
378757-83-6). Compound 3 diproprionate (propanoic acid, compound
3 with N,N-bis[3-(4,5-dihydro-1H-imidazol-2-yl) phenyl]urea [2:1])
(CAS number 55750-06-6) was used due to its relatively high degree of
solubility in water.
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inhibitory effect on the growth of Y. pestis at the concentrations
tested (Fig. 4A). To our surprise, the previously identified T3S
inhibitor INP0007 (compound 1 in reference 30) completely
inhibited growth at 60 M (Fig. 4A).
Direct cytotoxicity. The toxicities of compounds 1 to 4 for
HeLa cells were assessed in two ways: observing the effects on
cell morphology (rounding, detachment) and obtaining quan-
titative measurements of LDH release. Compound 2 caused
cell rounding and detachment, while the other compounds did
not when they were used within the range of concentrations
used in the T3S inhibition assays (data not shown). Consistent
with this observation, compound 2 also caused concentration-
dependent LDH release, while compounds 1, 3, and 4 also had
no effect in this assay (Fig. 4B).
Compounds 1, 3, and 4 inhibit T3S-mediated cytotoxicity.
One result of the delivery of effector proteins by the Y. pestis
system to cells in culture is a cytotoxic reaction characterized
by cytoskeletal dysfunction, resulting in cell rounding and de-
tachment (11). To determine if the compounds could inhibit
the delivery of effector proteins to HeLa cells, we examined
their ability to block this effect. Because compound 2 directly
caused similar effects (see above), only compounds 1, 3, and 4
were tested in this assay. All three compounds protected in-
fected HeLa cells from T3S-induced morphological changes.
The protection afforded by all three compounds was concen-
tration dependent (Fig. 5B). Although we did not measure the
rates of growth of the Y. pestis organisms in the medium sup-
plemented with the inhibitors used in these experiments, this
medium supplemented with the inhibitors at 60 M supported
the substantial growth of Y. pestis in overnight cultures.
Compound 3 inhibits translocation of a YopE::Bla fusion
protein to HeLa cells. The T3S-dependent morphological
change induced in mammalian cells is primarily caused by the
effector protein YopE, a GTPase-activating protein affecting
actin polymerization (11). Thus, inhibition of these morpho-
logical changes implies the inhibition of YopE translocation or
activity. A more direct assay for T3S effector translocation
based on the use of effector::-lactamase fusion proteins and
the cell-permeant florescent -lactamase substrate CCF2-AM
has been devised (24). Using this method, we tested the abil-
ities of compounds 1, 3, and 4 to block the translocation of a
YopE::Bla fusion from Y. pestis to HeLa cells. At 80 M,
compound 3 (diproprionate salt) completely inhibited translo-
cation in this assay, and at 40 M, it yielded an estimated 50%
inhibition (Fig. 6). Compounds 1 and 4 showed no obvious
effect in this assay. The latter result is somewhat surprising, as
both of these compounds inhibited T3S-mediated cytotoxicity
(Fig. 5B), a phenomenon dependent on Yop translocation.
One possible explanation for this result is that the cytotoxicty
reaction requires higher levels of Yop translocation to yield a
positive result than does the YopE::Bla-based fluorescent sub-
strate assay, at least under the conditions used in our experi-
ments. It is also possible that the YopE::Bla fusion protein is
less sensitive to inhibition than native Yops.
Compounds 1 and 3 also inhibit T3S in EPEC. To deter-
mine if the inhibitory effects of compounds 1 to 4 might extend
to T3SSs other than the T3SS of the yersiniae, we tested their
FIG. 3. Effects of selected compounds on Yop secretion. Repre-
sentative Western blots of YopM, YopH, and YopD in Y. pestis culture
supernatants 2 h after shifting of the incubation temperature from
30°C to 37°C to induce T3S for each compound are shown. Yop
secretion was quantified by densitometry, as described in Materials and
Methods. The means and standard deviations from at least three
independent experiments are plotted. (A) Compound 1; (B) com-
pound 2; (C) compound 3; (D) compound 4.
FIG. 4. Effects of compounds on Y. pestis growth and cytotoxicities
of the compounds for HeLa cells. (A) Effects of compounds on the
growth rate of Y. pestis. The exponential rate of growth of Y. pestis
JG153 in the presence of 60 M of the indicated compounds is re-
ported as a percentage of the rate observed in the absence of added
compound. The cultures contained TB broth with 2.5 mM Ca2 and
were incubated at 37°C with aeration. Means and standard deviations
from triplicate experiments are shown. Comp, compound. (B) Cyto-
toxicities of compounds 1 to 4, as determined by the LDH assay. HeLa
cells were treated with up to 60 M of compounds 1 to 4 (including
compound 3 as the diproprionate salt) at 37°C for 2 to 3 h. Aliquots of
the cell culture supernatants were sampled. The amounts of LDH
released by 0.1% Triton X-100-treated cells and untreated normal cells
were taken as LDHhigh and LDHlow respectively. Percent cytotoxicity
was calculated as [observed LDH  LDHlow)/(LDHhigh  LDHlow)] 
100. Error bars represent the standard deviations of the means from
three independent assays.
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ability to block T3S in EPEC. Unlike the Y. pestis system, the
T3SS of EPEC secretes effectors into the medium during
growth at 37°C without special treatment. In strain KC14 (8),
in the presence of compounds 1 and 3, the level of secretion of
the EPEC effector Tir was significantly reduced (Fig. 7). Com-
pounds 2 and 4 were tested at concentrations up to 60 M
(data not shown), but no inhibition was observed. KC21 (27)
was used as a T3S-negative control strain.
DISCUSSION
The HTS assay based on relieving the growth inhibition
associated with the in vitro activation of T3S secretion in Y.
pestis described above has proved to be both effective and
convenient. The rate of false-positive results was low, in the
sense that the screening of 70,966 compounds yield only 431
positive hits (0.6%), among which strong positive hits were
observed at a rate of 0.01%. Z values (43), a statistical mea-
sure of assay quality, between 0.5 and 1 are generally regarded
as excellent for HTS methods. In our HTS assay, the Z value
for random assay plates averaged 0.7 (31). The assay clearly
yields bona fide inhibitors. Addition of the test compounds to
the bacterial suspension in the appropriate medium is the only
preincubation manipulation required, and luminometry is the
only postincubation step. The use of a luminescent Y. pestis
derivative allows a reliable means of detection of modest
growth at low bacterial densities and avoids interference by
common artifacts (e.g., bubbles) that afflict direct measure-
ments of growth by determination of the OD. This method is
strongly biased against compounds that inhibit bacterial
growth, an effect that would yield false-positive results by some
other approaches. It also selects for compounds that act on the
bacteria rather than on target cells, as the latter are not present
in the assay. The chief disadvantage of this approach is that it
may fail to detect some classes of inhibitors because they do
not relieve growth inhibition. For example, compounds that
interfere at the level of formation of the connection of the
secretion apparatus with target cells would probably not be
detected.
Several other techniques have been used to screen for T3S
inhibitors. These include enzyme-linked immunosorbent assay-
based detection of proteins secreted from EPEC (19), inhibi-
tion of sheep erythrocyte lysis by EPEC (1), and inhibition of
induction of a yopE::luxAB fusion in Y. pseudotuberculosis. The
erythrocyte lysis assay probably depends on pore formation by
T3S translocon proteins (EspB and EpsD in EPEC, which are
paralogues of Yersinia YopB and YopD, respectively), while
FIG. 5. Lead compounds and cytotoxicity. The effects of the com-
pounds on the T3S-mediated cytotoxic response of HeLa cells exposed
to Y. pestis were determined. (A) HeLa cells exposed to Y. pestis JG153
(with pCD1 [pCD1], positive control) (left) and JG154 (without
pCD1 [pCD1], negative control) (right). The images were taken at
3 h and 18 h postinfection for low-magnification and high-magnifica-
tion images, respectively. (B) Inhibition observed following addition of
different concentrations of compound 1, compound 3 (diproprionate),
and compound 4 to HeLa cells exposed to Y. pestis. The morphological
changes in the HeLa cells were scored at 3 h postinfection. Percent
inhibition was calculated as {1  [(observed number of rounded
cells  number of rounded cells without cytotoxicity)/(number of
rounded cells with cytotoxicity  number of rounded cells without
cytotoxicity)]}  100. Error bars represent the standard deviations
of the means from three independent assays.
FIG. 6. Compound 3 diproprionate inhibits YopE-Bla transloca-
tion to HeLa cells. HeLa cells were infected with JG153(pMM85),
which expresses YopE-Bla, and were then incubated at 37°C for 3 h.
Compound 3 diproprionate was added to the cell culture at the time of
infection. CCF2-AM was added, and live cells were visualized by flu-
orescence microscopy. pCD1, cells negative for pCD1; pCD1, cells
positive for pCD1; Bla, -lactamase.
FIG. 7. Compounds 1 and 3 inhibit T3S by EPEC cells. Bacterial
cultures treated with increasing concentrations of the indicated com-
pounds were centrifuged, and the resulting pellets were lysed. Immu-
noblots prepared from these samples were stained with anti-OmpA
antibody (OmpA is an E. coli outer membrane protein) to provide a
measure of bacterial density. Immunoblots stained with anti-HA were
prepared from TCA precipitates of the culture supernatant to provide
a measure of secreted HA-tagged Tir, a T3S substrate in EPEC.
(A) Compound 1; (B) compound 3 diproprionate salt. On the basis of
estimates derived from densitometry of the immunoblots, 60 M com-
pound 1 blocks Tir secretion by 96%, while 60 M compound 3
reduces Tir secretion by 81%.
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the yopE::luxAB fusion assay depends on the observation that
the induction of T3S in the yersiniae is accompanied by sub-
stantial increases in the levels of transcription of effector genes,
including yopE (22). Each of these approaches has yielded
some potential inhibitors. The yopE::luxAB fusion method has
been used most extensively, because, like our method, it is well
suited to HTS. Initial experiments by the use of this method
yielded 4 lead compounds from the screening of 9,400 com-
pounds from the ChemBridge DiverSet F library. Initial
structure-activity relationship studies (13, 21, 30) have been
performed with two of these compounds, a salicylaldehyde
compound (previously designated INP0007 [20]) and a 2-aryl-
sulfonylamino-benzanilide, by using activity assays based on
whole bacteria, because the targets of these compounds are not
established. The activities of INP0007 and selected analogs
against both Salmonella enterica serovar Typhimurium have
been tested in vitro and in a tissue culture model (20, 29), and
the activities of these compounds against Chlamydia trachoma-
tis have been tested in tissue culture (2, 28). The results of
these studies are consistent with the inhibition of T3S in these
species.
The inhibitory compounds identified in our assay are a di-
verse group and in all cases are distinct from those discussed
above. One interesting feature of the inhibition data is the
differential action of the inhibitors on the secretion of different
Yop species. Only compound 2 acted effectively against all
three Yop species examined, while each of the other com-
pounds inhibited YopH secretion more effectively than they
inhibited the secretion of YopD and YopM. Moreover, the
relative activities against the secretion of YopD and YopM
also varied among the compounds. These differences suggest
that the compounds differ in their mechanisms of action. The
abilities of compounds 1 and 3, but not those of compounds 2
and 4, to inhibit the secretion of Tir by EPEC provides addi-
tional evidence that the mechanisms of action are diverse. Like
INP0007 and related compounds, the novel scaffolds of com-
pounds 1 and 3 clearly indicate that they have spectra of ac-
tivity that extend beyond the yersiniae. This confirms the utility
of the Yersinia system as a general platform for identifying T3S
inhibitors.
Compound 2 was remarkable in comparisons with the other
T3S inhibitors described here and elsewhere for its low IC50
and its ability to cause very complete inhibition. While the
toxicity of this compound for mammalian cells is unfortunate,
studies of its mechanism of action against T3SSs may prove
useful in the development of improved inhibitors. It is also
possible that modifications of this compound may sufficiently
reduce its toxicity to provide a useful therapeutic index.
One puzzling observation is that INP0007 inhibited the
growth of both Y. pestis and Y. pseudotuberculosis, with stronger
inhibition against the former being observed. This conflicts
with the results of Kauppi et al. (22). We cannot explain this
inconsistency and can only suggest that it may be due to dif-
ferences in the growth medium used or may be due to the
presence of a minor but potent growth inhibitor in our com-
mercial preparation. Minor contaminants were observed by
mass spectroscopy (see Fig. S1 in the supplemental material),
but the effect of this compound on bacterial growth is an issue
that should be revisited.
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